Roble Belko & Company Inc Has $92,000 Stock Position in AbbVie Inc. (NYSE:ABBV)

Roble Belko & Company Inc increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 45.8% in the 4th quarter, HoldingsChannel reports. The firm owned 592 shares of the company’s stock after acquiring an additional 186 shares during the period. Roble Belko & Company Inc’s holdings in AbbVie were worth $92,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ABBV. TI Trust Inc. acquired a new stake in AbbVie during the third quarter worth approximately $204,000. AFS Financial Group LLC bought a new position in AbbVie in the third quarter worth approximately $234,000. OneAscent Financial Services LLC boosted its holdings in AbbVie by 24.6% in the third quarter. OneAscent Financial Services LLC now owns 6,030 shares of the company’s stock worth $899,000 after acquiring an additional 1,191 shares in the last quarter. Strategic Advisors LLC boosted its holdings in AbbVie by 2.1% in the third quarter. Strategic Advisors LLC now owns 78,456 shares of the company’s stock worth $11,695,000 after acquiring an additional 1,615 shares in the last quarter. Finally, PSI Advisors LLC boosted its holdings in AbbVie by 5.5% in the third quarter. PSI Advisors LLC now owns 4,410 shares of the company’s stock worth $657,000 after acquiring an additional 231 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.9 %

Shares of ABBV stock traded up $1.53 during trading hours on Monday, reaching $167.94. The company had a trading volume of 5,580,360 shares, compared to its average volume of 5,635,411. AbbVie Inc. has a 12 month low of $130.96 and a 12 month high of $182.89. The company has a debt-to-equity ratio of 5.02, a current ratio of 0.87 and a quick ratio of 0.76. The business has a fifty day simple moving average of $175.34 and a 200-day simple moving average of $160.42. The company has a market cap of $297.36 billion, a price-to-earnings ratio of 61.52, a price-to-earnings-growth ratio of 2.14 and a beta of 0.58.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, February 2nd. The company reported $2.79 EPS for the quarter, topping analysts’ consensus estimates of $2.76 by $0.03. The business had revenue of $14.30 billion for the quarter, compared to analyst estimates of $14.02 billion. AbbVie had a return on equity of 162.28% and a net margin of 8.95%. AbbVie’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period last year, the company posted $3.60 earnings per share. On average, research analysts expect that AbbVie Inc. will post 11.16 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a dividend of $1.55 per share. The ex-dividend date is Friday, April 12th. This represents a $6.20 dividend on an annualized basis and a yield of 3.69%. AbbVie’s dividend payout ratio (DPR) is currently 227.11%.

Insider Buying and Selling

In related news, EVP Azita Saleki-Gerhardt sold 52,870 shares of AbbVie stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $173.71, for a total transaction of $9,184,047.70. Following the sale, the executive vice president now directly owns 243,944 shares in the company, valued at $42,375,512.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other AbbVie news, EVP Jeffrey Ryan Stewart sold 58,949 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $178.79, for a total value of $10,539,491.71. Following the completion of the sale, the executive vice president now directly owns 60,941 shares of the company’s stock, valued at $10,895,641.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Azita Saleki-Gerhardt sold 52,870 shares of the firm’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $173.71, for a total value of $9,184,047.70. Following the completion of the sale, the executive vice president now directly owns 243,944 shares of the company’s stock, valued at $42,375,512.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 383,324 shares of company stock worth $67,780,003. 0.25% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Truist Financial increased their price target on AbbVie from $180.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 6th. Raymond James increased their price target on AbbVie from $181.00 to $189.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. William Blair upgraded AbbVie from a “market perform” rating to an “outperform” rating in a report on Monday, January 29th. BMO Capital Markets increased their price target on AbbVie from $187.00 to $195.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Finally, Barclays increased their price target on AbbVie from $185.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, March 27th. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $177.43.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.